FDA to Address Female Sexual Enhancement Drugs

LOS ANGELES — The topic of female sexual dysfunction — and drugs to treat it — will be front and center at an FDA meeting this month, one in a series of 20 looking at “patient-focused drug development.”

Critics have accused the Food and Drug Administration of having a gender bias, pointing out that it has approved six male-targeted drugs to help them overcome anxiety, physiology and more to get an erection, but has yet to approve a single female equivalent. 

The meeting to be held Oct. 27-28 will include statements from patients about the impact that female sexual dysfunction has had on their lives, WebMD reports. It will also include a scientific workshop to discuss how to diagnose the disorder and measure how well medications for it work.

Advocating for pharmaceutical gender inclusivity is Even the Score, a campaign that launched in June and is backed by the drug companies of at least three potential treatments for female sexual dysfunction.

A petition to the FDA posted by Even the Score on Change.org attracted more than 16,000 signatures. The petition addresses the FDA: “We urge you to work fairly and urgently toward a solution to an unmet medical need…”

Others, including the National Women’s Health Network and the American Medical Women’s Association, believe that the dearth of pharmaceutical options for women is not a gender bias, but a reflection of how much more complicated treating female sexual dysfunction can be.  

Following, they have supported the FDA’s decisions not to approve a drug for female sexual dysfunction, arguing that women may need more than a single pill to boost their libido. Viagra and Cialis target one important aspect of sex — the erection — but do not address psychological aspects of arousal, which may be key for women’s satisfaction,

Cindy Pearson, executive director of the National Women’s Health Network, says while the FDA has not been immune to gender bias, she doesn’t believe that is what’s delaying the drugs. “If it were gender bias, we would be yelling and screaming,” Pearson said. “The problem is the drugs. Our biology is so much more complicated than men’s.”

Related:  

Copyright © 2026 Adnet Media. All Rights Reserved. XBIZ is a trademark of Adnet Media.
Reproduction in whole or in part in any form or medium without express written permission is prohibited.

More News

Kheper, Warm Human Launch New 'Gift Bags'

Kheper Games has partnered with Warm Human to launch seven new naughty and irreverent-themed gift bags.

A Look at the Latest Trends in Pleasure Products

Pleasure brands, retailers and distributors with their finger on the pulse of the market are sharing their observations on the latest trends from the past year that are driving sales.

Blush Expands 'Anal Adventures' Collection

Blush has introduced X-Large Anal Beads from its Anal Adventures Collection.

Xgen Debuts '4Play' Collection From Bodywand

Xgen Products has introduced the new 4Play collection of clitoral stimulators from its Bodywand line.

Lovense Debuts 'Fizz' Stimulator

Lovense has introduced its new Fizz dual-head clitoral stimulator.

SinParty Integrates Honey Play Box's Vibe-Connect Camming Tools

Cam platform SinParty has partnered with Honey Play Box to integrate the pleasure brand’s Vibe-Connect interactive camming software, allowing creators to engage fans and generate revenue through connected toys during and beyond livestreams.

Hankey's Toys Debuts DiYardieULuv2H8 Silicone Lifecast Dildo

Mr. Hankey's Toys has introduced its newest silicone lifecast dildo, modeled on the anatomy of creator DiYardieULuv2H8.

Blush Expands 'Avant' Line

Blush has introduced two new dildos from its Avant Collection.

Male Power Expands 'Sassy Lace' Collection

Male Power has expanded its new Sassy Lace collection of men's underwear.

Adam & Eve, We-Vibe to Launch Pop-Up Tour

Adam & Eve and We-Vibe have partnered for the nine-city “Experience an Ourgasm” pop-up tour, kicking off July 18.

Show More